Sun, March 15th, 2015- NQ (NQ Mobile Inc.) $3.55- This NASDAQ Small Cap Technology stock now coming off its recent lows of $3.22 per share could see a major move over the long term. The stock has fallen from its 52 week high of just over $20 dollars per share. Watch for a major bounce up to $10-$15 dollars a share range

Buy Zones- $3.22- $3.65

Targets- $10.00-$15.00 per share.


Thurs, January 29th, 2015- FRO (Frontline, Ltd) $2.43- This Energy Nasdaq Small cap stock mentioned earlier today via sms saw a low of $2.35 per share from its open of $2.83 per share.

Buy Zones- $2.35- $2.45

Targets- $2.70-$3.00 per share. (Please consider these as short term “trades”.)


Frontline Ltd.

is a major, Bermuda based, tanker company.

As a result of the acquisitions of vessels and companies since 1996, Frontline Ltd. has established itself as one of the world leaders in the international seaborne transportation of crude oil, with one of the world’s largest fleets of VLCC and Suezmax tankers.


The Company’s vision is to provide the customers with a flexible and reliable transportation service, and use this flexibility to develop unique industrial relations that will give material benefits to the customers as well as to the Company, shareholders and employees. Frontline’s business strategy is primarily based upon the following principles:

  1. emphasising operational safety and quality maintenance for all of its vessels;
  2. complying with all current and proposed environmental regulations;
  3. outsourcing technical operations and crewing;
  4. achieving low operational costs of vessels;
  5. achieving high utilisation of its vessels;
  6. competitive financing arrangements; and
  7. develop relationship to main charterers.

A large portion of Frontline’s vessels trade in the spot market. Spot market rates are typically higher than time charter rates to compensate for the lack of confirmed continual employment. After having delivered their cargo, spot market vessels typically operate in ballast (without cargo) until being rechartered. It is the time element associated with these ballast legs which Frontline seeks to minimise by efficiently chartering tankers. Frontline seeks to maximise earnings in employing vessels in the spot market or under time charters or under contracts of affreightment (“COA”).

Increasing global environmental concerns have created a demand in the petroleum products/crude oil seaborne transportation industry for vessels that are able to conform to the stringent environmental standards currently being imposed throughout the world.


Contact Info
  • Par-la-Ville Place
  • 14 Par-la-Ville Road
  • Hamilton HM 08
  • Bermuda


Wed, June 11th, 2014

AMCO (Armco Metals Holdings, Inc) .23 Cents

Bid:                                                       .23 Cents

Ask:                                                      .26 Cents

Targets:                                                $1 dollar plus


The Responsible Choice for the Chinese Steel Industry

Armco Metals holdings,Inc understands what it means to act responsibly—for the environment and the customers, suppliers, and investors who partner with us.

For the Environment

As one of the largest metal recyclers in China, we are focused on finding sustainable, dependable, and environmentally friendly ways to meet the steel industry’s demands. This includes the construction of our 32-acre, state-of-the-art scrap metal recycling facility, Armet (Lianyungang) Renewable Resource Co., Ltd. Processing up to one million metric tons of scrap steel annually, our recycling operations help reduce pollution and save energy. In contrast to iron ore, steel produced from recycled scrap requires 60% less energy and reduces air and water pollution by 86% and 76%, respectively. By aligning ourselves with China’s green initiatives, Armco Metals is helping the government reach its scrap metal consumption goal of 20% by 2015.

For our Partners

Just as we are dedicated to the environment, Armco Metals is dedicated to our customers, suppliers, and investors, providing them with every advantage possible for business success. By utilizing more than 10 years of experience and insights, we have built a strong and diverse sales channel that capitalizes on existing infrastructure, price incentives, and business relationships. Our subsidiaries are located in key regions throughout the country, improving our ability to source quality scrap steel and metal ores; reduce the cost of and logistics behind transportation; and allow us to maintain and deepen personal relationship with our partners. Armco Metals has long-standing relations with more than 10 international metal suppliers and 100 small- and medium-sized Chinese steel production businesses, creating a steady, dependable supply and demand for quality product at excellent market values. And as the shift toward renewable solutions for the steel industry continues, Armco Metals will build upon this framework and expand our recycled scrap steel operations to meet this growing need.

Armco Metals Project Development

Armco Metals Holdings,Inc is one of the leading recycled scrap steel sales and distribution companies in China. With more than 10 years of experience in the sourcing and distributing metal and non-ferrous metal ore to the Chinese steel production industry, we have developed long-standing relationships with more than 100 small- and medium-sized metal producers throughout the country, as well as more than 10 international metal suppliers from countries such as Australia, South Korea, India, Brazil, and the United States


Contact Info
  • One Waters Park Drive
  • Suite 98
  • San Mateo, CA 94403

1) NYSE stock book value is $1.20 dollars per share

2) Total asset 81 million dollars

3) Total liabilities 41 million dollars

4) Total equity 40 million dollars

5) Total outstanding shares 33.7 million

6) AMCO insiders holding 33% of shares

7) AMCO was trading at 10 dollars in 2010



Wed, March 12th, 2014

AEZS (AEterna Zentaris Inc.)           $.51

Bid:                                                      $.49

Ask:                                                     $.51

Targets:  $2- $5 Medium to Long Term (potential targets only)



AEZS a medical Biotech company located in Canada has a significant amount of drugs in the pipeline that are entering the Phase 3 approval. The First is the Catalyst Cancer Drug which can hit any time. About Macimorelin Acetate (AEZS-130) Macimorelin acetate, a ghrelin agonist, is a novel orally-active small molecule that stimulates the secretion of growth hormone. The Company has completed a Phase 3 trial for use in evaluating AGHD, and has submitted a NDA to the FDA in this indication. Macimorelin acetate has been granted orphan drug designation by the FDA for use in AGHD. Furthermore, macimorelin acetate is in a Phase 2 trial as a treatment for cancer-induced cachexia. Aeterna Zentaris owns the worldwide rights to this novel patented compound.  In conclusion we believe on successful FDA approvals the stock could possibly see a major move of up to $10 to $30 dollars per share this year.

Contact Info

  • 1405, boul. du Parc-Technologique
  • Quebec, QC G1P 4P5
  • Canada

Recent News

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2013 Financial and Operating Results on March 20, 2014

QUEBEC CITY, March 12, 2014 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) will announce its fourth quarter and full-year 2013 financial and operating results after market close on Thursday, March 20, 2014. The Company will host a conference call to discuss these results on Friday, March 21, 2014, at 8:30 a.m., Eastern Time.


Participants may access the live webcast via the Company’s website at in the “Newsroom” section, or by telephone using the following numbers: in Canada, 514-807-9895 or 647-427-7450, outside Canada, 888-231-8191. A replay of the webcast will also be available on the Company’s website for a period of 30 days.

About Aeterna Zentaris

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company’s pipeline encompasses compounds at various stages of development. For more information, visit

SOURCE Aeterna Zentaris Inc.

Copyright 2014 PR Newswire


Aeterna Zentaris: Article on Phase 2 Results for Zoptarelin Doxorubicin in Endometrial Cancer Published in the International …
Aeterna Zentaris Inc. (MM) (NASDAQ:AEZS)

QUÉBEC CITY, Feb. 4, 2014 /PRNewswire/ – Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced that an article on Phase 2 results for zoptarelin doxorubicin (AEZS-108) in endometrial cancer has been published in the February issue of the  International Journal of Gynecological Cancer. Zoptarelin doxorubicin, is the Company’s cytotoxic peptide conjugate which specifically targets luteinizing hormone-releasing hormone (“LHRH”) receptors. The article, “Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)”, Emons G., Gorchev G., Harter P., Wimberger P., Stähle A., Hanker L., Hilpert F., Beckmann M.W., Dall P., Gründker C., Sindermann H., Sehouli J., outlines results of this study which had been previously presented at the European Society of Gynaecological Oncology’s (“ESGO”) annual meeting inSeptember 2011. The article is currently available at this link.

“These encouraging results were the basis for our current Phase 3 ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) trial in women with advanced, recurrent or metastatic endometrial cancer who have progressed and have received one chemotherapeutic regimen with platinum and taxane”, stated David Dodd, President and CEO of Aeterna Zentaris. “This compound’s innovative targeted approach potentially offers a much needed novel treatment option for women with endometrial cancer and could provide the Company with a significant market opportunity.”

Phase 2 Study Results and Conclusion

Forty-four patients were entered onto the study at 8 centers in Germany and 3 centers in Bulgaria. Forty-three of these patients were eligible. Two patients had a complete remission (5%) and 8 achieved a partial remission (18%). Stable disease for at least 6 weeks was observed in 44%. The median time to progression (TTP) was 7 months and median overall survival (OS) was 15 months. The most frequently reported grade 3 or 4 adverse effects were neutropenia (12%) and leucopenia (9%).

Data showed that zoptarelin doxorubicin has clinically meaningful activity with low toxicity in women with advanced or recurrent LHRH receptor positive endometrial cancer, supporting the principle of receptor mediated targeted chemotherapy.

Current ZoptEC Phase 3 trial in endometrial cancer

This is an open-label, randomized, multicenter Phase 3 trial currently being conducted under a Special Protocol Assessment, comparing zoptarelin doxorubicin with doxorubicin as second line therapy for advanced, recurrent or metastatic endometrial cancer. The first patient was dosed in July 2013 and recruitment is ongoing at multiple sites in North America, Europe and Israel. The primary efficacy endpoint is improvement in median Overall Survival. Lead investigators are David Scott Miller, MD, from the University of Texas Southwestern Medical Center, in Dallas, Texas, and Hani Gabra, MD, from the Imperial College London Hammersmith Campus in London, England.

Selected as the contract clinical development organization, Ergomed has agreed to assume 30% (up toUS$10 million) of the clinical and regulatory costs for this trial. Details for this trial are available at (NCT01767155).

About Zoptarelin Doxorubicin

Zoptarelin doxorubicin represents a new targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin. Zoptarelin doxorubicin is the first intravenous drug in advanced clinical development that directs the chemotherapy agent specifically to LHRH-receptor expressing tumors, resulting in a more targeted treatment with less damage to healthy tissue. The Company is currently conducting a Phase 3 trial in endometrial cancer under a Special Protocol Assessment, while zoptarelin doxorubicin is also in an investigator-initiated Phase 2 trial in prostate cancer. Aeterna Zentaris owns the worldwide rights to this compound.


About Endometrial Cancer

Endometrial cancer is the most common gynecologic malignancy in developed countries and develops when abnormal cells amass to form a tumor in the lining of the uterus. It largely affects women over the age of 50 with a higher prevalence in Caucasians and a higher mortality rate among African Americans. According to the American Cancer Society, an estimated 49,560 new cases of endometrial cancer in the U.S., and 35,600 inEurope were expected during 2013, with about 20% of recurring disease.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company’s pipeline encompasses compounds from drug discovery to regulatory approval. For more information, visit